randomized phase 2 study of Docetaxel+CBDCA versus weekly Paclitaxel+CBDCA

INTERVENTION: docetaxel and carboplatin weekly paclitaxel and carboplatin CONDITION: ovarian cancer PRIMARY OUTCOME: progression free survival SECONDARY OUTCOME: quality of life ,safety INCLUSION CRITERIA: Patients with histologically or cytologically confirmed epitheral ovarian cancer, fallopian tubal cancer or peritoneal cancer. performance status(ECOG)0‐2. no prior chemotherapy. adequate levels of bone marrow,hepatic,and renal function. n. no heart failure and pulmonary disease. no active infection. no other malignancies. signing of an informed consent document.